DKN-01 DeFianCe Data Update

DeFianCe Study Preliminary Results - In the DKK1-high subgroup (upper quartile), sirexatamab showed a 32% higher response rate by Investigator Assessment (48% vs 16%) [11, 12, 14, 15] - In the DKK1-high subgroup (upper quartile), sirexatamab showed a 35% higher response rate by BICR (40% vs 5%) [16, 17] - In the DKK1-high subgroup (upper quartile), sirexatamab resulted in a 3.5-month longer Progression-Free Survival (PFS) with a median of 9.36 months vs 5.88 months (HR 0.46, p = 0.0248) [18, 20] - In the DKK1-high subgroup (upper quartile), sirexatamab significantly improved Overall Survival (OS) with a median not yet reached vs 9.49 months (HR 0.09, p = 0.0018) [21, 23] VEGF-Naive Population - In the no prior anti-VEGF subgroup, sirexatamab improved ORR by 22% (55% vs 33%) by Investigator Assessment (p=0.0116) [27, 28, 29, 30] - In the no prior anti-VEGF subgroup, sirexatamab doubled ORR (45% vs 22%) as assessed by BICR (p=0.0066) [31, 32] - In the no prior anti-VEGF subgroup, sirexatamab resulted in a 2.6-month longer Progression-Free Survival (PFS) with a median of 10.94 months vs 8.34 months (HR 0.59, p = 0.0386) [33, 35] Intent-to-Treat (ITT) Population - In the Intent-to-Treat (ITT) population, sirexatamab improved ORR by 10% (36% vs 26%) by Investigator Assessment (p = 0.0536) [41, 42, 43] - In the Intent-to-Treat (ITT) population, sirexatamab improved ORR by 17% (33% vs 16%) as assessed by BICR (p = 0.0023) [45, 46] Market Opportunity - DKK1 biomarker high represents approximately 25%-50% of the global second-line colorectal cancer (2L CRC) market [57, 60] - VEGF-naïve patients are expected to represent approximately 50% of the global 2L market [57, 60]